





Prenatal maternal plasma DNA screening for cystic fibrosis: A



























 Nicholas J. Wald ( )Corresponding author: n.j.wald@qmul.ac.uk
  : Conceptualization, Formal Analysis, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; Author roles: Old RW




 Old RW, Bestwick JP and Wald NJ. How to cite this article: Prenatal maternal plasma DNA screening for cystic fibrosis: A computer
   2017,  :1896 (doi: modelling study of screening performance [version 1; referees: 2 approved] F1000Research 6
)10.12688/f1000research.12849.1
 © 2017 Old RW  . This is an open access article distributed under the terms of the  , whichCopyright: et al Creative Commons Attribution Licence
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 The author(s) declared that no grants were involved in supporting this work.Grant information:












 27 Oct 2017,  :1896 (doi:  )First published: 6 10.12688/f1000research.12849.1
 27 Oct 2017,  :1896 (doi:  )Latest published: 6 10.12688/f1000research.12849.1
v1
Page 1 of 14
F1000Research 2017, 6:1896 Last updated: 08 NOV 2017
Introduction
Cystic fibrosis (CF) is a severe monogenic autosomal recessive 
inherited disorder. Over 1,000 mutations have been documented1. 
In Europe, CF prevalence is about 1 in 2500 live births2,3, with 
about 1 in 25 people being a carrier4. In current prenatal screening, 
parental CF carrier testing identifies couples who are both carriers 
and offers an invasive diagnostic procedure (amniocentesis or 
chorionic villus sampling [CVS]) to expectant mothers, one in four 
of whom will have an affected pregnancy5–8.
Detecting paternal CF mutations in DNA from maternal plasma 
as a possible alternative screening method fails because in about 
50% of cases the paternal and maternal CF mutations are the 
same9. The screening method described here overcomes this and 
does not require parental CF carrier testing. It relies on sequencing 
and counting DNA fragments, as currently carried out in prenatal 
DNA screening for Down syndrome10–12. Unlike carrier testing, 
which aims simply to detect the presence or absence of mutations 
in each parent, our method depends on determining the proportion 
of mutant and non-mutant DNA fragments in maternal plasma. 
We describe how this proportion can be determined with suffi-
cient statistical precision to distinguish affected from unaffected 
pregnancies.
The DNA analysis pathway is summarized in Box 1. Plasma DNA 
comprises short fragments that are typically 100–200bp. Primer 
pairs are used to hybridise with target sites within about 150bp in 
the CFTR gene for polymerase chain reaction (PCR) amplification 
of DNA regions that include specified CF mutations. Plasma DNA 
fragments are tagged with barcodes that provide unique molecu-
lar identifiers of each DNA fragment. Such tagging adjusts for 
and minimises variation in the ratio of mutant to non-mutant DNA 
sequences that arises from the PCR13–15. The number of DNA frag-
ments with and without a CF mutation are counted after massively 
parallel DNA sequencing of the amplified products.







Addition of unique molecular identifiers
↓
Targeted amplification of DNA regions containing CF mutations
↓
Massively parallel DNA sequencing of targeted regions
  ↓
Identify DNA fragments with CF mutations and DNA fragments 
without CF mutations
  ↓
Using the unique molecular identifiers discard excess replicates 
of individual DNA fragments generated in the amplification step
  ↓
Estimate percentage of fragments with a CF mutation
This concept paper uses results from computer modelling to 
estimate the number of DNA fragments to be counted at each CF 
mutation site, and the number of CF mutation sites to be analysed 
to achieve good expected discrimination between affected and 
unaffected pregnancies. We then estimate the expected population 
screening performance of the method.
Methods
Estimating maternal plasma distributions of the percentage 
of targeted CF DNA fragments with a CF mutation
An affected pregnancy is one in which a fetus has a CF mutation 
on each of the pair of chromosomes 7; other pregnancies, includ-
ing those with fetuses that are CF carriers, are designated 
unaffected. For any CF mutation site, the expected (mean) 
percentage of DNA fragments with a CF mutation in affected and 
unaffected pregnancies was determined for a given fetal fraction 
(the proportion of plasma DNA from the placenta). These expected 
percentages depend on whether the DNA analysis detects two 
different CF mutations. If not, there are four possible situations, 
illustrated in Figure 1. In case A in the figure (an affected 
pregnancy with a 10% fetal fraction), the mother’s plasma will, in 
expectation, contribute 45% of DNA fragments with a CF muta-
tion and the fetus 10%, i.e. a total of 55%. We estimated the 
distribution of the percentages of DNA fragments with a CF 
mutation in affected  and unaffected pregnancies for specific 
fetal fractions using Gaussian distributions with a mean m and 
a standard deviation (100 ) / ,m m n× −  where n is the number 
of  sequenced DNA fragments in the mutation site. There is one 
distribution in affected pregnancies with an expected mean of 
(100-ff) / 2 (maternal contribution to all CF fragments) + ff (the 
fetal contribution), where ff is the fetal fraction. There are four 
distributions in unaffected pregnancies; (i) if neither parent is 
a carrier the mean and the standard deviation are zero, (ii) if the 
mother but not the fetus is a carrier the expected mean is (100-ff)/2, 
(iii) if the fetus is a carrier, with the mutation inherited from the 
mother the expected mean is (100-ff)/ 2 +ff/2, (iv) if the fetus is a 
carrier with the mutation inherited from the father the mean is ff/2.
Where two different CF mutations are found in the maternal 
plasma, only the predominant CF mutation (i.e. the more abundant 
mutation, which is always the one inherited from the mother) is 
informative. For example, in an affected pregnancy with a 10% 
fetal fraction, the mother’s plasma will, in expectation, contribute 
45% of DNA fragments with a CF mutation and the fetus 10%, 
half of which is from the father and can be disregarded, i.e. 50% 
of DNA fragments at the relevant site have a CF mutation. As 
above, we estimated the distribution of percentages in affected and 
unaffected pregnancies for specified fetal fractions. The expected 
mean of the distribution in affected pregnancies is (100-ff)/2 + ff/2 
and is (100-ff)/2 if the fetus is a carrier.
The distributions were derived for increasing numbers of DNA 
fragments counted (the more counted, the larger n, and the smaller 
the standard error) and for different fetal fractions (the larger the 
fetal fraction, the more separated the distributions) to determine the 
minimum counts needed to obtain complete or near complete sepa-
ration of the distribution in affected and unaffected pregnancies. A 
positive result was defined as one in which the percentage of DNA 
fragments with a CF mutation was equal to or greater than a speci-
fied cut-off. A screen negative result was one with values below the 
cut-off.
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The above analyses were applied to the 23 CF mutations selected 
by the American College of Medical Genetics and the American 
College of Obstetrics and Gynecology16 for parental carrier 
testing, taking account of their separate prevalence in the pan- 
ethnic standard population, accounting for an estimated 83.4% of 
CF carriers.
Estimating population screening performance
The detection rate (DR, sensitivity: proportion of affected pregnan-
cies with a positive result) was estimated from the proportion of the 
total area under the distribution of percentage of DNA fragments 
with a given CF mutation in affected pregnancies equal to or greater 
than specified cut-off levels, multiplied by the proportion of all CF 
mutations in the population attributable to the CF mutations in the 
panel.
The false-positive rate (FPR: proportion of unaffected pregnancies 
with a positive result), was estimated from the proportion of the 
total area under the distributions of the percentage of DNA frag-
ments with a given CF mutation in unaffected pregnancies equal 
to or greater than the specified cut-off levels, multiplied by the 
proportion of all CF mutations in the population attributable to 
the CF mutations in the panel. We adjusted for confined placental 
mosaicism involving trisomy 7 by taking account of its preva-
lence and the 50% chance that the extra chromosome has the CF 
mutation17–19.
The population odds of being affected given a positive result 
(OAPR) was estimated from the DR divided by the FPR times the 
prevalence of CF expressed as an odds. The pregnancy prevalence 
of CF was taken to be 1 in 2500, or 1:2499 as an odds.
Results
Distribution of percentage of DNA fragments with a CF 
mutation
Figure 1 shows the percentage of DNA fragments with a CF 
mutation in maternal plasma from an affected pregnancy when 
the two CF mutations are the same (XX) (i.e. only one CF muta-
tion found) according to parental CF carrier status (OX = carrier, 
OO = unaffected non-carrier). The figure is based on a 10% fetal 
fraction. If the fetus is affected, the percentage of DNA fragments 
with the CF mutation in the maternal plasma is, in expectation, 
55%. If the fetus is unaffected and is not a carrier, it is 45% or 
0% (depending on the parental carrier status). If the fetus is a CF 
carrier, it is 50% or 5% (again depending on the parental carrier 
status). In this way, affected pregnancies are distinguished and 
a result of 55%, which can be statistically separated from the 
expected 50% or less, defines a positive screening result.
Figure 2 shows the percentage of DNA fragments with a CF 
mutation in maternal plasma in an affected pregnancy when the 
two CF mutations are different (X1 and X2) (i.e. two CF mutations 
found) according to parental CF carrier status. The fetal fraction 
Figure 1. Expected (mean) percentage DNA fragments with a cystic fibrosis (CF) mutation in CF affected and unaffected pregnancies 
if the fetal fraction is 10%. One or no CF mutation found.
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is taken as 10%. In maternal plasma the predominant mutation is 
necessarily from the mother. The expected percentage of CF muta-
tions at the predominant CF mutation site in an affected pregnancy 
is 50% and 45% in an unaffected pregnancy.
Figure 3 shows the estimated relative distributions of DNA 
fragments with one or no CF mutation found according to fetal 
fractions (10%, a typical value, and 4%, a lower limit typically 
used in prenatal DNA Down syndrome screening)20–22, the number 
of DNA fragments sequenced that include the mutation site, and 
whether the pregnancy is affected or unaffected. With a 10% fetal 
fraction, counting 8,000 sequenced DNA fragments gives almost 
complete separation of the relative distributions for the three 
possible fetal genotypes, with complete (or near complete) 
discrimination, and consequently a very low FPR. With a 4% 
fetal fraction, counting 32,000 targeted fragments still gives good 
discrimination between affected and unaffected pregnancies.
Figure 4 shows the relative distributions of the percentage of DNA 
fragments with a CF mutation according to fetal fraction if 32,000 
DNA fragments are counted. Figure 4A applies if one or no CF 
mutations are found, and Figure 4B if two different CF mutations 
are found. Figure 4A shows that with a 3% or greater fetal fraction, 
there is good discrimination between affected and unaffected 
pregnancies, but less so with a 2% fetal fraction.
Figure 4B shows that when two different mutations are found the 
mean for the predominant CF mutation in affected pregnancies is 
always 50% regardless of the fetal fraction. This is also shown in 
Figure 2 with a 10% fetal fraction. If the fetal fraction were 4%, 
the contributions from the mother and the fetus would still sum to 
50% i.e. 2% + 48% instead of 5% + 45% as in Figure 2. In an unaf-
fected pregnancy in which the fetus is a carrier, the mean increases 
towards 50% with decreasing fetal fraction and consequently the 
cut-off to determine a positive test result is dependent on the fetal 
fraction. As in Figure 4A, with a 3% or greater fetal fraction, there 
is good discrimination, but not with a 2% fetal fraction.
The effect of confined placental mosaicism
Confined placental mosaicism involving trisomy 7, with an esti-
mated prevalence of 0.2%17,18, has a small influence on the FPR. 
This effect arises from pregnancies in which the fetus is a CF carrier 
and has inherited the CF mutation from the mother, and the placen-
tal mosaicism is 0XX. This results in more than the expected 50% 
of DNA fragments with the CF mutation in the maternal plasma. 
The increase depends on the fetal fraction. Instead of the (unaf-
fected) carrier fetus contributing half fetal fraction to the proportion 
of mutant fragments in the maternal plasma, it will be two-thirds 
fetal fraction, i.e. an increase of one-sixth fetal fraction. Given that 
the mother and fetus are both carriers, and in the estimated 0.1% of 
pregnancies with confined placental mosaicism of the OXX type, 
this shift in the distribution of mutant DNA fragments increases the 
FPR. For example, with a cut-off of 51%, a fetal fraction of 10% 
and 32,000 DNA fragments counted, the effect of confined placen-
tal mosaicism contributes about 0. 002% to the FPR (prevalence 
of OXX type of confined placental mosaicism (0.1%), times the 
prevalence of mother and fetus carrier status (2%), times the pro-
portion of CF mutations in the population included in the ACMG 
Figure 2. Expected (mean) percentage DNA fragments with the predominant cystic fibrosis (CF) mutation in CF affected and unaffected 
pregnancies if the fetal fraction is 10% and two mutations are found. Two different CF mutations found.
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Figure 3. Relative distributions of percent DNA fragments with a cystic fibrosis (CF) mutation in affected and unaffected pregnancies 
according to fetal fraction and number of targeted DNA fragments sequenced. One or no CF mutation found. 
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Figure 4. Relative distributions of percent DNA fragments with a CF mutation in affected and unaffected pregnancies according to 
fetal fraction (32,000 targeted DNA fragments sequenced). (A) One or no CF mutation found; (B) Two different cystic fibrosis (CF) mutations 
found.
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panel (0.834) , and making the conservative assumption that nearly 
all of these false positives would be shifted across the 51% cut-off). 
Our estimates of screening performance take account of this 
correction to the FPR. The prevalence of confined placental 
mosaicism of either the OXX or OOX type (0.1%) is sufficiently 
low to have a negligible effect on the DR.
Population screening performance
The 23 CF mutations in the selected panel account for an 
estimated 83.4% of people with a CF mutation, so the maximum 
CF DR (proportion of CF pregnancies detected) is 70% 
(83.4% × 83.4%), because for a fetus to be affected it must have 
two CF mutations, one from each parent, assuming random 
mating.
Table 1 shows the estimated screening performance according to 
the screening cut-off (expressed as the percentage of targeted DNA 
fragments with a CF mutation), and fetal fraction using the 23 CF 
mutation panel. The cut-off of choice is 51% when one or no CF 
mutation is found in the maternal plasma sample. When two CF 
mutations are found in the maternal plasma, the cut-off will vary 
according to fetal fraction (eg. 46% with a 10% fetal fraction or 
49% with a 4% fetal fraction. Provided the fetal fraction is 3% or 
more, a DR of 67–70% (limited mainly because of the number of 
mutations used in the test, not by the DNA analysis) can be achieved 
with a very low FPR (≤ 0.002%). Counter-intuitively, the OAPR 
increases with decreasing fetal fraction. This arises as a result of 
two competing effects; an underlying decrease in the OAPR with 
decreasing fetal fraction and a diminishing false-positive rate due 
to the placental mosaicism, the latter dominating. Even in the pres-
ence of placental mosaicism a low fetal fraction is a disadvantage 
because of the reduced detection rate. Table 1 also shows that the 
DR is reduced to 35% with a 2% fetal fraction, setting a practical 
lower limit of 3%; <1% of pregnancies have a fetal fraction <3%20. 
The 70% DR shown in Table 1 requires the use of 23 CF mutations 
in the test and an estimated 736,000 targeted DNA fragments need 
to be counted (23 mutations × 32,000 fragments per mutation).
Discussion
Prenatal DNA screening for CF has a higher predicted screening 
performance than conventional screening based on parental carrier 
testing. The improved screening performance is based on main-
taining the DR achieved using a given parental carrier testing CF 
mutation panel but with a 60 times lower FPR, 0.002% compared 
Table 1. Screening performance according to cut-off of 
percentage of targeted DNA fragments with a CF mutation and 
fetal fraction (32,000 DNA fragments sequenced per mutation in 
the 23 CF mutation panel) using the 23 common mutation panel 
recommended by the American College of Medical Genetics16.
Cut-off  
(% of DNA fragments 
with a CF mutation)
Fetal 





DR (%) FPR (%) OAPR
20 50 40 70 0.8 1:29
51 41 70 0.002 14:1
52 42 70 0.002 14:1
10 50 45 70 0.8 1:29
51 46 70 0.002 14:1
52 47 70 <0.001 130:1
4 50 48 70 0.8 1:29
51 49 70 <0.001 140:1
52 50 35 <0.001 >1000:1
3 50 48.5 70 0.8 1:29
51 49.5 67 <0.001 420:1
52 50.5 3 <0.001 >1000:1
2 50 49 70 0.8 1:29
51 50 35 <0.001 860:1
52 51 <0.1 <0.001 >1000:1
*Cut-off to yield same screening performance as when only 1 mutation is found.
DR=detection rate; FPR=false-positive rate; OAPR=odds of being affected given 
a positive result
If FPR < 0.001% OAPR is precise unless over 1000:1.
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with 0.12% (prevalence of carrier couples is 4% × 4% = 0.16%, 
assuming random mating and, among these, 75% are false-positive 
(0.16% × 0.75 = 0.12%)).
Figure 5 compares prenatal CF screening based on parental carrier 
testing with plasma DNA screening. The figure shows its clinical 
advantage in achieving a much lower FPR and hence a much higher 
OAPR, 42 times higher (14:1/ 1:3) than parental carrier testing. An 
estimated 98% of invasive diagnostic tests in unaffected pregnan-
cies are avoided, without loss of detection (82/84 in Figure 5).
The selection of a screening cut-off of targeted DNA fragments 
with a CF mutation should balance maximizing the DR, minimiz-
ing the FPR, and achieving an acceptably high OAPR. A cut-off of 
51% is reasonable (Table 1). This cut off, with a 10% fetal fraction, 
achieves an expected 70% DR with a FPR of 0.002%. A higher cut-
off of 52% results in a loss of detection with low fetal fractions even 
though the FPR is decreased. A 50% cut-off retains detection but at 
the cost of a much increased FPR.
Plasma DNA screening is simpler than parental carrier testing 
because it only requires a maternal plasma sample. It also avoids 
a problem with parental carrier based screening that arises when 
the biological father (but not the assumed father) is a carrier, and 
the pregnancy is affected. The rate of non-paternity varies among 
populations; in one study it was 2%23.
Plasma DNA screening treats each pregnancy as a fresh screen-
ing opportunity, which is similar to prenatal screening for neural 
tube defects or Down syndrome. The screening aims to identify an 
affected pregnancy. There is no intention to identify carriers, which 
is a benefit from a screening perspective, because almost all carriers 
will never have an affected pregnancy. Being a carrier is of minor or 
no medical consequence. The fact that the disorder being screened 
for is inherited is, from the screening perspective, irrelevant. This 
approach has the advantage of screening women who have a preg-
nancy with a different partner without the need to retrieve a report 
on her previously determined carrier status, and if a carrier, deter-
mining the carrier status of her new partner.
Unique molecular identifiers are needed to overcome random error 
in DNA fragment amplification. With the use of unique molecular 
identifiers amplification, sequencing, and counting can be corrected 
for under- and over-amplification13–15. Plasma DNA sequencing 
as described here, using unique molecular identifiers, overcomes 
the limitation associated with digital PCR24 that does not quantify 
mutant and non-mutant DNA sequences sufficiently accurately to 
reliably distinguish affected from unaffected pregnancies. Whole-
genome sequencing could overcome the digital PCR limitation, 
but is impractical because of the cost of unnecessary sequencing 
of most of the genome25. Our paper provides a potentially practical 
cost-effective solution, the screening algorithms needed, and com-
puter modelled estimates of population screening performance.
To obtain the 32,000 DNA fragments containing a CF mutation site 
needed for the test if the fetal fraction is as low as 2% requires 
about 13ml of plasma (i.e. about 30ml blood), because 1ml typi-
cally contains about 2400 haploid (single duplex DNA strand) 
whole genomic equivalents, each of which has one copy of each CF 
mutation site26,27 (32,000/ 2,400). Figure 6 illustrates how 13.3ml 
of plasma provides enough target sites to distinguish an affected 
fetus from a maternally derived fetal carrier fetus (one CF mutation 
Figure 5. Illustration of prenatal screening for cystic fibrosis (CF) based on A parental CF carrier testing using the 23 common mutation 
panel recommended by the American College of Medical Genetics16 and B screening using the maternal plasma DNA with the same 23 CF 
mutations (fetal fraction 10%, 51% cut-off if one CF mutation found, 46% if 2 found [see Table 1]).
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Figure 6. Illustration of number of DNA fragments at a CF mutation site in a pregnancy where the fetus is affected and the fetal 
fraction is 2%, compared with the number in a pregnancy where both the mother and fetus are carriers (one CF mutation is found).
found). There would be enough blood for a DNA screening test for 
trisomy 21, 18, and 13, as well as CF. The plasma DNA test should 
cost little more than about half the cost of a Down syndrome DNA 
screening test because sequencing accounts for about half the test 
cost, and the sequencing cost of the CF test is reduced to about a 
tenth or less of that required for Down syndrome screening
As the number of CF mutations used in the test increases, the 
number of DNA fragments to be counted also increases without, 
however, requiring a larger plasma sample because many CF 
mutation sites can be amplified simultaneously14. Using 23 
CF mutations, 736,000 (23 × 32,000) DNA fragments need to be 
counted. Adding prenatal CF screening to DNA-based screening 
for Down syndrome is feasible and involves only an extra step to 
amplify the selected CF DNA sites prior to sequencing.
The number of CF mutations tested limits the overall DR. Some 
current parental carrier testing uses more CF mutations than the 23 
used here; one programme uses a 106 mutation panel, accounting 
for an estimated 91% of people with a CF mutation in the popula-
tion specified. This yields an 81% DR (91% × 91%). A panel of 
about 100 mutations should be feasible with maternal plasma DNA 
screening; however, the incremental increase in detection with 
increasing number of CF mutations is very small. Any panel used 
could be modified according to the ethnic distribution of the popu-
lation screened. Maternal plasma DNA screening using full exon 
sequencing (which would include all CF mutations) may be a future 
option, but there may be a limit to the number of DNA regions that 
can be amplified.
While plasma DNA screening does not rely on parental CF carrier 
detection, it still has a useful role to play where CF carrier testing 
has already been established. The relevant CF mutations would be 
known from parental testing and, provided the parental CF muta-
tions were included in the method, all affected pregnancies would 
be identified and amniocentesis or chorionic villus sampling would 
be avoided in nearly all unaffected pregnancies. Therefore, about 
3/4 women would avoid an invasive diagnostic procedure.
The proposed method could be used in a two-step screening proce-
dure in which the CF carrier status of the mother is first identified 
and then, if she is a carrier, the described method adopted. This may 
have cost savings as, if the mother is not a carrier, there is no need 
to proceed with further testing. Also, it would lend itself to other 
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autosomal recessive disorders. The method described here need not, 
therefore, be limited to CF.
Although de novo CF mutations are rare, the proposed method 
detects them, provided they are included in the specified mutation 
set. Interpretation of test results if the fetus has a de novo mutation 
applies as set out in this paper, with three exceptions: (i) mother is 
not a carrier but the father is a carrier - in this situation the percent-
age DNA CF fragments is on average 10% if the mutation is the 
same as the father’s mutation or 5% if it is different (assuming a 
10% fetal fraction); (ii) mother and father are carriers, the father 
carries a different CF mutation, the de novo mutation is the same 
as the father’s mutation and the fetus inherits the father’s muta-
tion - in this situation the affected pregnancy would be missed; 
(iii) mother and father are carriers, the father carries with a 
different mutation, the fetus has a mutation that is different from 
both and the fetus inherits the father’s mutation - in this situation 
the affected pregnancy would be detected by the presence of three 
different CF mutations. While in one of these situations an affected 
pregnancy would be missed, the method achieves a higher level of 
detection than screening based on parental carrier testing, which 
misses all cases with a de novo mutation except for those where 
both parents are carriers.
Conclusion
Prenatal maternal plasma DNA screening for CF has an estimated 
screening performance substantially higher than current screen-
ing based on parental carrier testing. While amniocentesis is still 
required for the diagnosis of CF, the proposed method means that 
nearly all amniocenteses would be performed in affected pregnan-
cies, without reducing the DR. The overall expected advantages 
are sufficiently large to merit developing the test for use in routine 
screening practice and evaluation in a clinical validation study.
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